Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb;11(1):292-300.
doi: 10.21037/cdt-20-335.

Innovative transcatheter procedures for the treatment of heart failure

Affiliations
Review

Innovative transcatheter procedures for the treatment of heart failure

Francesco Saia et al. Cardiovasc Diagn Ther. 2021 Feb.

Abstract

The prevalence of heart failure (HF) continues to rise over time, with aging of the population and increased survival of incident cases. Major improvements occurred in drug therapy but morbidity and mortality of HF patients remain high. Some non-pharmacologic approaches to HF are already part of standard treatment for HF, including implantable cardioverter-defibrillators, cardiac resynchronization therapy (CRT) and left ventricular assist devices (LVADs). A number of transcatheter treatments and devices have been developed to improve management of valvular heart diseases (VHD), and some of them are being used or tested in specific HF conditions. For example, transcatheter aortic valve implantation (TAVI) to unload the left ventricle in patients with moderate aortic stenosis (AS) and HF or TAVI for severe aortic regurgitation (AR) in patients with LVADs. Similarly, percutaneous mitral valve repair can be used to improve prognosis and quality of life in patients with functional mitral valve regurgitation, and has been proposed as a bridge-to-LVAD or to heart transplant in selected patients. Other devices have been specifically developed for the treatment of chronic HF. In this review we describe the main devices used in the treatment of HF associated with aortic and mitral valve disease, as well as novel transcatheter interventions for chronic HF with different pathophysiologic targets.

Keywords: Heart failure (HF); left ventricular assist device (LVAD); left ventricular dysfunction; percutaneous mitral valve repair; secondary mitral regurgitation; transcatheter aortic valve replacement.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure forms (available at http://dx.doi.org/10.21037/cdt-20-335). The series “Heart Failure in the Young and Old: Insights into Various Therapies” was commissioned by the editorial office without any funding or sponsorship. FS reports personal fees from Abbott Vascular, personal fees from Edwards, personal fees from Medtronic, personal fees from Boston Scientific, personal fees from Astra Zeneca, personal fees from Daiichy-Sankyo, personal fees from Amgen, personal fees from Bayer, personal fees from Boheringer-Ingelheim, outside the submitted work. The authors have no other conflicts of interest to declare.

Figures

Figure 1
Figure 1
Targets of new transcatheter options for patients with heart failure. AS, aortic stenosis; FMR, functional mitral regurgitation; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; LV, left ventricle; PA, pulmonary artery; TAVI, transcatheter aortic valve implantation; TR, tricuspid regurgitation.
Figure 2
Figure 2
The Revivent TCTM device. (A)* Illustration of the procedure. (B)* Focus on the nitinol anchors for plication of the left ventricular aneurism. (C) Intra-operative fluoroscopic image. *, from https://bioventrix.com/index.php/it/medico/sistema-revivent-tc.

Similar articles

Cited by

References

    1. Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation 2020;141:e139-e596. 10.1161/CIR.0000000000000757 - DOI - PubMed
    1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891-975. 10.1002/ejhf.592 - DOI - PubMed
    1. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017;38:2739-91. 10.1093/eurheartj/ehx391 - DOI - PubMed
    1. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017;70:252-89. 10.1016/j.jacc.2017.03.011 - DOI - PubMed
    1. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med 2019;380:1695-705. 10.1056/NEJMoa1814052 - DOI - PubMed